详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.

文献详情

资源类型：

作者：

机构： [1]Peking University People's Hospital, Beijing, China. [2]Gachon University Gil Hospital, Incheon, Korea. [3]National Taiwan University Hospital, Taipei, Taiwan. [4]Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. [5]Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonnam, Korea. [6]West China Hospital of Sichuan University, Chengdu, China. [7]Seoul National University Hospital, Seoul, Korea. [8]Sungkyunkwan University, Samsung Medical Centre, Seoul, Korea. [9]Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China. [10]National Cancer Centre, Gyeonggi-do, Korea. [11]Beijing Chao-Yang Hospital, Beijing, China. [12]The Catholic University of Korea, Seoul, Korea. [13]Hallym University Sacred Heart Hospital, Anyang, Korea. [14]Seoul National University Bundang Hospital, Seongnam, Korea. [15]Chonbuk National University Hospital, Jeonju, Korea. [16]Celgene Corporation, Summit, NJ, USA. [17]Hospital University Centre (CHU), Bordeaux, France. [18]Service des Maladies du Sang, H?pital Claude Huriez, Lille, France.

出处：

DOI：

ISSN：

关键词： lenalidomide multiple myeloma transplant-ineligible newly diagnosed Asia

摘要：

The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Given genetic differences between Asian and Western populations, this subanalysis of the FIRST trial examined the safety and efficacy of Rd (given continuously or for 18 cycles [Rd18]) and MPT (melphalan, prednisone, thalidomide) in 114 Asian patients from Mainland China, South Korea and Taiwan. Efficacy and safety with Rd continuous in Asian patients were consistent with those in the overall study population. The overall response rates were 77·8% for Rd continuous, 57·5% for MPT and 65·8% for Rd18. The risk of progression or death was reduced by 39% with Rd continuous versus MPT and by 35% with Rd continuous versus Rd18. Rd continuous improved the 3-year survival rate compared with MPT (70·2% vs. 56·4%) and Rd18 (58·1%). Common grade 3/4 adverse events in the Rd continuous and MPT arms were neutropenia (25·0% vs. 43·6%), infection (19·4% vs. 28·2%) and anaemia (19·4% vs. 15·4%), respectively. Thromboembolic event rates were low, and no second primary malignancies were observed. Rd continuous is safe and effective in transplant-ineligible Asian patients with NDMM. © 2017 The Authors. British Journal of Haematology Published by John Wiley & Sons Ltd.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区血液学

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区血液学

第一作者：

第一作者机构： [1]Peking University People's Hospital, Beijing, China.

通讯作者：

通讯机构： [18]Service des Maladies du Sang, H?pital Claude Huriez, Lille, France. [*1]Chef du P^ole des Specialites Medicales et Oncologiques, Chef du Service des Maladies du Sang, CHRU rue Michel Polonovski, 59037 Lille, France.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. [2]Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma [3]DVD和VAD方案治疗初治多发性骨髓瘤的疗效和安全性分析 [4]A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma [5]Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis [6]BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions. [7]Pathogenesis and treatment of multiple myeloma. [8]Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. [9]RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor [10]多发性骨髓瘤疾病全周期健康管理